Cover Image
市場調查報告書

鼻結膜炎:開發中產品分析

Rhino-Conjunctivitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 363111
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
鼻結膜炎:開發中產品分析 Rhino-Conjunctivitis - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 66 Pages
簡介

本報告提供鼻結膜炎治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

鼻結膜炎概要

治療藥的開發

  • 開發中產品的概要

鼻結膜炎:企業開發中的治療藥

鼻結膜炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

鼻結膜炎:企業開發中的產品

鼻結膜炎治療藥的開發企業

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • ASIT biotech s.a.
  • Bial - Portela & Ca, S.A.
  • Circassia Pharmaceuticals Plc
  • Faes Farma, S.A.
  • Griffin Discoveries BV
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.
  • Laboratorios LETI S.L.
  • Oxagen Limited
  • Roxall Medizin GmbH
  • Stallergenes SAS

鼻結膜炎:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

鼻結膜炎:暫停中的計劃

鼻結膜炎:中止開發的產品

鼻結膜炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9482IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2017, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 7, 8, 1 and 1 respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rhino-Conjunctivitis - Overview
    • Rhino-Conjunctivitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Rhino-Conjunctivitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma GmbH & Co KG
    • Allergy Therapeutics Plc
    • ASIT Biotech SA
    • Astellas Pharma Inc
    • Bial - Portela & Ca SA
    • Faes Farma SA
    • Griffin Discoveries BV
    • HAL Allergy BV
    • Laboratorios LETI SL
    • Oxagen Ltd
  • Rhino-Conjunctivitis - Drug Profiles
    • Acaroid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergovac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-4070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gp-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hdm-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OC-2417 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pollinex Quattro Tree - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Timapiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rhino-Conjunctivitis - Dormant Projects
  • Rhino-Conjunctivitis - Discontinued Products
  • Rhino-Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI 2017
      • Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study
      • May 18, 2014: BioTech Tools will be present at the EAACI congress
      • Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics
      • Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites
      • Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil
      • Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
      • Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study
      • Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain
      • Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries
      • Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Rhino-Conjunctivitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Allergopharma GmbH & Co KG, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H1 2017
  • Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Faes Farma SA, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Griffin Discoveries BV, H1 2017
  • Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H1 2017
  • Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H1 2017
  • Rhino-Conjunctivitis - Dormant Projects, H1 2017
  • Rhino-Conjunctivitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Rhino-Conjunctivitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top